Broad-Spectrum Free-Form Amino Acid Supplements: Formulation Rationale, Mechanisms, Clinical Evidence and Dose Transferability of an 18-Component Formulation (Amino Complex)

Abstract

Background: Free-form amino acid supplements are marketed for muscle, metabolic, neurological, vascular, digestive and connective-tissue support, but the evidence derives almost entirely from single amino acids or complete essential-amino-acid mixtures at the gram scale. Broad-spectrum blends distributing a sub-gram total across many constituents have not been appraised.

Objective: To evaluate the rationale for this class and establish how far gram-scale ingredient evidence transfers to finished formulations of this type, with an 18-component composition as reference example.

Methods: Structured critical narrative review reported against SANRA and PRISMA-S. Five databases were searched from January 2016 to July 2026. Evidence was assigned to one of two layers — finished-product or ingredient-level — graded by Oxford CEBM level, and every efficacy dose recorded with its fold-difference from the reference quantity.

Results: The reference formulation supplies 897.5 mg of amino acids, 274 mg of them indispensable; L-threonine is absent. No study of any comparable finished formulation was identified. Mechanistic plausibility is strong: leucine and arginine each have a named molecular sensor upstream of mTORC1, and methionine is sensed indirectly through S-adenosylmethionine. Transferability is nonetheless limited by three independent factors: first-pass mucosal catabolism, near-complete for dietary glutamate and aspartate and 30–50 % for arginine and the branched-chain amino acids, together 44.9 % of the formulation; competitive rather than additive transport of a third of its mass at one blood–brain barrier carrier; and dose gaps of roughly five- to two-hundred-fold. Every constituent with a published reference value sits 35- to 1,000-fold below that ceiling.

Conclusion: Supplements of this class are best characterised as broad-spectrum dietary sources of amino acid substrates with wide safety margins and a coherent biochemical rationale; efficacy claims are not supportable at these quantities. Where the dose gap is narrowest, composition rather than total quantity is the operative constraint.